GenScript Receives "Best Contract Development and Manufacturing Organization Award" For the Third Time in a Row
PR95238
SINGAPORE,March30,2022/PRNewswire=KYODO JBN/--
GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) receives the
"Best Contract Development and Manufacturing Organization Award" on the Asia
Pacific Bioprocessing Excellence Awards 2022. This marks the third consecutive
year of GenScript bagging the same award in Asia Pacific region. The award also
follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in
2021 for the "Best Contract Development and Manufacturing Organization Award".
"We are honored to be recognized once again by our customers and industry peers
as the leading CDMO service partner to the biopharmaceutical industry. This
award is a solid testament to our continuous effort and dedication to maintain
our global position as the top solutions and service provider to accelerate
drug development, next generation vaccines and therapies", said Dr. Kun Yin,
Senior Director of Business Development, GenScript ProBio Asia Pacific
division. "We will continue to strive for excellence by leveraging our
technology platforms and expertise to provide the best solution to our
customers and partners."
Asia Pacific Bioprocessing Excellence Awards 2022 recognizes exceptional
bioprocessing experts, organizations and technologies that facilitate
biomanufacturing excellence at enhanced speed, reduced cost, and superior
quality. The panel of expert judges include Key Opinion Leaders with more than
20 years of experience, Process Development Vice Presidents and Directors,
Heads of Manufacturing and Bioprocessing from all the key players in Asia and
globally. GenScript emerges as the winner for the best CDMO award among the
industry peers in Asia Pacific region.
In January 2022, GenScript ProBio, which is the CDMO division of GenScript
broke ground for the construction of its newest 34,000 square meter plasmid and
viral vector manufacturing facility. The facility will be state-of-the-art,
utilizing the latest technology and equipment in viral vector and plasmid
manufacturing to scale up its production capacity and deliver end-to-end cell
and gene therapy CDMO services. Many projects for COVID-19 mRNA vaccine from
China have been carried out in GenScript ProBio's plasmid manufacturing
facility. Besides supporting many mRNA vaccine enterprises in China to obtain
clinical approvals by NMPA, GenScript ProBio also helped mRNA vaccine projects
from South Korea and the United States companies to obtain clinical approvals
in South Korea and Japan.
"Cell and gene therapy is the forefront of innovation to treat severe and rare
diseases, in the coming years, GenScript will focus on putting our dedication
and investment to partner with scientists and develop drugs and therapies to
improve human lives." said Dr. Kun Yin during the award ceremony.
About GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is the world's leading
technology and service provider of life science R&D and manufacture. Built upon
its solid gene synthesis technology, GenScript Biotech is divided into four
major platforms including the life science service and product platform, the
biologics contract development and manufacturing organization (CDMO) platform,
the global cell therapy platform and the industrial synthesis biological
product platform.
GenScript Biotech was founded in New Jersey, US in 2002 and listed on the Hong
Kong Stock Exchange in 2015. GenScript Biotech's business operations span over
100 countries and regions worldwide with legal entities located in the US,
Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and
Ireland. GenScript Biotech provides premium, convenient and reliable services
and products for over 100,000 customers.
As of December 31, 2021, GenScript Biotech had more than 5,200 employees
globally, over 40% of whom hold master's and/or Ph.D. degrees. In addition,
GenScript Biotech owns a number of intellectual property rights, including over
180 patents, over 670 pending patent applications and great numbers of trade
secrets.
Driven by the corporate mission of "making people and nature healthier through
biotechnology", GenScript Biotech strives to become the most trustworthy
biotech company in the world. As of December 31, 2021, GenScript Biotech's
services and products have been cited by 65,600 peer-reviewed journal articles
worldwide.
For more information, please visit GenScript Biotech's official website
About GenScript ProBio – Biologics CDMO
GenScript ProBio is the subsidiary of GenScript Biotech Corporation,
proactively providing end-to-end CDMO service from drug discovery to
commercialization with proactive strategies, professional solutions and
efficient processes in gene and cell therapy (GCT), vaccine, biologics
discovery and antibody protein drug to accelerate drug development for
customers.
GenScript ProBio's total gene and cell therapy solution covers CMC of plasmid
and virus for IND filing as well as clinical manufacturing and commercial
manufacturing. GenScript ProBio's innovative solutions for biologics discovery
and development include therapeutic antibody discovery, antibody engineering
and antibody characterization. GMP capacity which meets FDA, EMA and NMPA
regulatory requirements.
Toward the mission of "Innovation through Collaboration", GenScript ProBio is
committed to helping customers shorten the timeline for the development of
biological drugs from discovery to commercialization, significantly lowering
R&D costs and building a healthier future.
Source: Genscript
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=418116
Link: http://asianetnews.net/view-attachment?attach-id=418119
Caption: Dr. Kun Yin, Senior Director of Business Development, GenScript ProBio Asia
Pacific division receiving the best CDMO award on the virtual ceremony.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。